Article
The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Molecular cancer therapeutics - 1 May 2014
Musi Elgilda, Ambrosini Grazia, de Stanchina Elisa, Schwartz Gary K
Abstract excerpt
G-protein mutations are one of the most common mutations occurring in uveal melanoma activating the protein kinase C (PKC)/mitogen-activated protein kinase and phosphoinositide 3-kinase (PI3K)/AKT pathways. In this study, we described the effect of dual pathway inhibition in uveal melanoma harboring GNAQ and GNA11 mutations via PKC inhibition with AEB071 (sotrastaurin) and PI3K/AKT inhibition with BYL719, a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
